CN100450539C - Use of medicinal composition containing pilose antler for treating chronic brain blood supply deficiency - Google Patents
Use of medicinal composition containing pilose antler for treating chronic brain blood supply deficiency Download PDFInfo
- Publication number
- CN100450539C CN100450539C CNB200410019831XA CN200410019831A CN100450539C CN 100450539 C CN100450539 C CN 100450539C CN B200410019831X A CNB200410019831X A CN B200410019831XA CN 200410019831 A CN200410019831 A CN 200410019831A CN 100450539 C CN100450539 C CN 100450539C
- Authority
- CN
- China
- Prior art keywords
- parts
- blood supply
- rat
- cerebral blood
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to a novel application of a medical composition in the field of pharmacy, which belongs to the field of medicine. In the present invention, a chronic brain insufficient blood supply model of a rat is established by ligating common carotid arteries on both sides, and the rat is administered by intragastric administration. Through the certification of results, the learning and memory functions and the vertigo latent phase of rats administered by the medical composition in the group are obviously better than those of rats in a control group (P is less than 0.05).
Description
Technical field
The invention belongs to field of medicaments, be specifically related to a kind of application of pharmaceutical composition in preparation treatment chronic insufficient cerebral blood supply medicine that contains Rhizoma Chuanxiong.
Background technology
The origin of notion
Chronic insufficient cerebral blood supply (Chronic Cerebral Circulation Inefficiency, CCCI) blood supply that refers to the brain integral level reduces the state of (being lower than 40-60ml/100g cerebral tissue/per minute), but not focal cerebrum ischemia.It is the new name of disease of year proposition surplus in the of external preceding 10.The old age or the presenium patient that often have some to tell subjective symptomss such as nose heave, dizziness repeatedly clinically, except ocular fundus arteriosclerosis, both also not have cranium brain CT unusual for the focal sign of impassivity infringement, and these patients often are diagnosed as " cerebral arteriosclerosis ".As everyone knows, there are difference in the notion of cerebral arteriosclerosis and clinical diagnosis standard long-term.The chaos of conception that the so-called cerebral arteriosclerosis name of disease of always using for fear of people causes, Japanese health ministry has entrusted " about the definition and the diagnostic criteria tutorial class of cerebral arteriosclerosis disease " to study, cerebral arteriosclerosis has been made the corrigendum motion, think that previously cerebral arteriosclerosis, broad sense system include pathological notion of all diseases related that cerebral arteriosclerosis such as lacuna infarction causes; Narrow sense then refers to because cerebral arteriosclerosis causes the conscious slight neural mental symptom that is produced under the pathological state of disturbance of cerebral circulation, the focal sign of impassivity system and to stare at imaging examination unusual.The 16th apoplexy association of Japan formally was referred to as it chronic cerebral circulatory failure (Chronic Cerebral Circulation Inefficiency), i.e. CCCI in 1991.
International research shows that the harm of chronic insufficient cerebral blood supply is a lot.Specifically be summarized as follows:
● the atrophy of cortex atrophy----cortex is the basic pathological change that causes senile dementia
● the neurogenous degeneration of Hippocampus
● frontal lobe, Hippocampus M type cholinoceptor combination rate decline alba are loosened--and-Yi causes occurring hypomnesis, retrograde amnesia occurs
● glial cells hyperplasia---cause brain function to descend
● capillary bed changes
● other neural subjective symptoms obstacle
The diagnosis of CCCI
For CCCI is studied all sidedly, Japan scholar horizontal well is divided into 3 groups with the age the old man more than 60 years old, the A group is: subjective symptoms outbreaks such as dizziness, carebaria are arranged, more than the ocular fundus arteriosclerosis KWII, but do not have also Non Apparent Abnormality person of any focal neurosigns, CT scan; The B group is: except that subjective symptomss such as no dizziness, other conditions are identical with the A group: the C group is cotemporary healthy old men. and these three groups are all carried out CT, MRI, TCD and PET and check. and check result is: (1) TCD measures common carotid artery blood flow and shows that the .A group all significantly lowers for two groups than B, C; (2) PET shows Interhemispheric blood flow, and the A group significantly lowers than the C group; (3) MRI finds to have in the A group 55%, has 15% old man to find to have cerebral infarction or lacuna infarction in B and the C group.Its conclusion is: cerebral blood flow lowers near normal 80%, subjective symptomss such as dizziness just may occur; The appearance of mental symptom and nervous symptoms then must be lower than below 80% by blood flow.It should be noted that. the patients' of these dizzy outbreaks TCD and PET to be checked find. the blood flow in carotid artery system and cerebral hemisphere perfusion district thereof and the blood flow of vertebra basilar artery lower equally, therefore clinically dizzy symptom is belonged to vertebro-basilar artery insufficiency without exception seem comprehensive inadequately.Japanese health ministry blood circulation diseases tutorial class (1990) is studied the diagnostic criteria of having worked out CCCI in view of the above, sees the following form 1.
Table 1 chronic insufficient cerebral blood supply (CCCI) diagnostic criteria (one)
(1996) such as nearly rattans make further research 60 routine CCCI patients with said method, except that obtaining above-mentioned similar result of study, still observing CCCI patient further descends with the age growth common carotid artery blood flow, the all sites cerebral blood flow of each cerebral lobe and brain oxidative metabolism rate all descend obviously, think because atherosclerosis risk factors such as hypertension have caused the sclerosis of the mobile arteries and veins of brains.Cause diffuse cerebral blood flow and brain poor metabolism to produce the subjective symptoms of CCCI.Performance is not focal in view of the CCCI cerebral lesion, thus do not occupy transient ischemic attack (transient ischemic attack) category, and drawn more practical CCCI diagnostic criteria (seeing the following form 2).
Table 2 chronic insufficient cerebral blood supply (CCCI) diagnostic criteria (two)
Be born in 2000 the up-to-date diagnostic criteria of CCCI, its particular content is as follows:
" CCCI diagnostic criteria " version in 2000
1. subjective symptomss such as dizziness, headache, head sink;
2. the finding of supporting cerebral arteriosclerosis is arranged: (1) is with hypertension, ocular fundus arteriosclerosis change etc.; Or the vascular murmur of (2) audible and brain perfusion sometimes tremulous pulse;
3. the focal neurosigns that does not have brain;
4.CT having the organic brain of vascular, MRI do not change;
5. get rid of the above-mentioned subjective symptoms that other diseases causes;
6. the age is in principle greater than 60 years old (can be loosened to more than 45 years old);
7. cerebral circulation confirms that cerebral blood flow is low;
8.DSA or TCD prompting brain perfusion tremulous pulse has inaccessible or narrow change.
Compare with early stage version diagnostic criterias in 96 years, this edition standard is opinion, clear and definite more.Its typing sees the following form 3.
The international typing of table 3 chronic insufficient cerebral blood supply
Over past ten years, domestic many scholars compare comprehensive clinical research to CCCI, the blood properties such as blood viscosity fluid rheology index of observing most of CCCI patients reaches Fibrinogen unusually and obviously raises, and thinks that these also have bigger influence to the formation of CCCI or the fluctuation of symptom unusually; CT sees at the end unusual many patients. cranium brain MRI often can detect ischemic focus (the T1 weighted signal is no abnormal, T2 weighting and proton become to protect the slightly high signal of visible stigma point-like); Adopt the TCD dynamic measurement except that common carotid artery, main vascular flow lowers in the brain of still visible many places, for the clinical diagnosis of CCCI has increased new content.
The treatment of CCCI
According to table 1 and table 3, all dizzinesses that the undulatory property growth and decline are arranged, subjective symptoms such as nose heave, CT, MRI do not see vascular brain organic focus person, should belong to simple property CCCI, be considered to the cerebral infarction state of generation last stage, be necessary to carry out positive control, need improve the risk factor (as hypertension, diabetes, hyperlipemia, obesity etc.) of cerebral circulation and removal ischemic cerebrovascular (ICW), preferably adjoin anti-platelet aggregation medicines such as pyridine with aspirin, thiophene chlorine simultaneously, several days clinical subjective symptomss.And TCD or PET measure brain trunk tremulous pulse are arranged (vertebral-basilar artery system or/carotid artery system) blood flow reduction person, belong to compensatory phase CCCI, should take corresponding prevention and health care measure at the ICVD risk factor that exists, symptoms such as clinical appearance dizziness, CT shows ischemic brain material change (cerebral infarction, lacuna infarction), and TCD or PET confirm to have cerebral blood flow attenuating person.Then belong to CCCI II type or III type, should press lacuna infarction or cerebral infarction respectively and handle.
At present, the medicine for the treatment of the CCCI use clinically has: THA: cholinesterase inhibitor, GST-21: maincenter type N cholinoceptor inhibitor, FK506: immunosuppressant, Nimsuperzine:Cox-2 inhibitor etc., all obtained recent preferably clinical efficacy, late result remains further to be studied.Traditional Chinese medicine of China is having unique effect aspect the treatment CCCI.
The Chinese medicine sedative is the medicine that ancient Chinese medicine doctor is used always, comprises Ramulus Uncariae Cum Uncis, Semen Ziziphi Spinosae (parched), Caulis Polygoni Multiflori, Cortex Albiziae etc., has removing heat-phlegm, suppressing the hyperactive liver effect such as calm the nerves.Modern pharmacology confirms that sedative has sedation.
Through secular clinical practice, chosen the pharmaceutical composition of forming by Cornu Cervi Pantotrichum, Radix Polygoni Multiflori, Herba Epimedii etc. by the people, has benefiting QI and nourishing blood, spermatogenesis is mended marrow, the effect of invigorating brain and relieving mental uneasiness is used for sexual impotence due to deficiency of kidney essence, the decline of the fire from the gate of life clinically, is insomnia, disease such as headache, and seeing has impotence or act and not hard, insomnia forgetfulness, pale tongue with white fur etc.Modern times are used for sexual neurasthenie more, autonomic nervous dysfunction, and climacteric syndromes etc. have the deficiency of kidney essence proposita.
But relevant this medicine composite for curing chronic insufficient cerebral blood supply effect does not appear in the newspapers as yet.
Summary of the invention
The object of the invention is to provide the new purposes of aforementioned pharmaceutical compositions aspect the treatment chronic insufficient cerebral blood supply.
The prescription of this pharmaceutical composition is formed as follows by weight ratio:
20～40 parts in Cornu Cervi Pantotrichum, 600～650 parts of Radix Polygoni Multiflori Preparatas, 450～550 parts of Herba Epimedii, 100～150 parts of Rhizoma Zingiberiss, 60～65 parts in Radix Glycyrrhizae, 100～150 parts in Fructus Jujubae, vitamin B
11～10 part.
Best proportioning is:
30 parts in Cornu Cervi Pantotrichum, 625 parts of Radix Polygoni Multiflori Preparatas, 500 parts of Herba Epimedii, 125 parts of Rhizoma Zingiberiss, 62.5 parts in Radix Glycyrrhizae, 125 parts in Fructus Jujubae, vitamin B
15 parts.
Aforementioned pharmaceutical compositions can be made any one dosage form on the pharmaceutics, and wherein oral liquid is implemented by following scheme:
The material of getting it filled according to the above ratio: 30 parts in Cornu Cervi Pantotrichum, 625 parts of Radix Polygoni Multiflori Preparatas, 500 parts of Herba Epimedii, 125 parts of Rhizoma Zingiberiss, 62.5 parts in Radix Glycyrrhizae, 125 parts in Fructus Jujubae, vitamin B
15 parts; Rhizoma Zingiberis is extracted volatile oil, and medicinal residues and Radix Polygoni Multiflori Preparata, Herba Epimedii, Fructus Jujubae, Radix Glycyrrhizae decoct with water three times, and 2 hours for the first time, second and third time each 1 hour, merge extractive liquid, filters, and filtrate is condensed into fluid extract, adds ethanol precipitation, filters filtrate for later use; With Cornu Cervi Pantotrichum extracting in water 5 times, the time was followed successively by 4,4,3,3,2 hours, filtered merging filtrate respectively, be concentrated into 1/2 of primary dose, add Cera Flava, leave standstill solidify fully to the Cera Flava layer after, remove the dewax layer, sucking filtration adds 80% ethanol to clear and bright, room temperature left standstill 24 hours, filtered filtrate recycling ethanol, be concentrated in right amount, add ethanol, placed 24 hours under the room temperature, filter, filtrate recycling ethanol adds water and ethanol and regulates concentration to 10% (contain very is 20%～30%); With above-mentioned medicinal liquid, Cornu Cervi Pantotrichum extracting solution and simple syrup mixing add Rhizoma Zingiberis volatile oil, and vitamin B1 and benzoic acid mix, and leave standstill, and add water, promptly.
Chronic insufficient cerebral blood supply (CCCI) has close getting in touch with brain symptoms such as dizziness, headaches, but at aspects such as pathogenesis and Therapeutic Method tangible difference is arranged again.At present, for chronic insufficient cerebral blood supply, also mainly be based on the pharmaceutical intervention treatment, there is not clear and definite medicine.The medicine of treatment headache not necessarily has the effect of treatment chronic insufficient cerebral blood supply, even also can cause other untoward reaction.
In order to understand the present invention better, oral liquid formulation (hereinafter to be referred as " oral liquid ") treatment chronic insufficient cerebral blood supply rat model below by the observation aforementioned pharmaceutical compositions is dizzy, the influence of learning and memory, and the therapeutical effect of this pharmaceutical composition aspect the treatment chronic insufficient cerebral blood supply is described.
Experimental example: this medicine composite for curing chronic insufficient cerebral blood supply experimentation
One, materials and methods
1. animal grouping: 100 of male SD rats, in 10 ages in week, body weight 250 ± 20g is divided into 3 groups at random: oral liquid group, nimodipine group, model control group, every group each 20.Oral liquid group 8 weeks after modeling began to gavage this pharmaceutical composition 2g/kg/ days, once a day, and continuous 4 weeks; The nimodipine group substitutes oral liquid with equal-volume nimodipine (500ug/kg), and is surplus with the oral liquid group; Model control group substitutes oral liquid with the equal-volume normal saline, and is surplus with the oral liquid group.Medicine: nimodipine, nimodipine tablet, Shanxi Yabao Pharmaceutical Co., Ltd. produces, and lot number is that the accurate word (196) of medicine is defended No. 048095 in the Shanxi, every day 3 times, each 20mg, oral; This drug composition oral liquid is according to embodiment 1 method production.
2. rat chronic cerebral blood supply insufficiency model development: with reference to Torre[Torre Jc, Fortint, park GA, et al.ChroniccereBRovascular insufficiency induces dementia-induces dementia-like deficits in agedrats.Brain Res, 1992,582 (2): 186-195.] etc. method is made rat both sides ligation of carotid models (2VO).Rat is got the cervical region median incision and cuts off skin through being fixed in behind the 10% chloral hydrate 3.0ml/kg intraperitoneal injection of anesthesia on the operation plate, and passivity is separated each layer tissue, see in the neck that the external carotid artery bifurcated separates vagus nerve, prick bilateral common carotid arteries, layer-by-layer suture with the 4-0 toe-in.Keep 37 ℃-38 ℃ of anus temperature, 23 ℃ of postoperative feeding environment temperature, free diet in the art.
3. learning and memory is measured: adopt Y type maze experiment.Rat is placed in the Y type labyrinth box, began experiment after conforming 3 minutes.The rat of shocking by electricity successively clockwise, the learning and memory in rats achievement has 9 correct required number of shocks to represent to reach in continuous 10 times, how much represent the quality of learning and memory function with reaching 9/10 correct required number of shocks.Laboratory animal respectively at 2VO before, respectively carry out Y type labyrinth test and record achievement behind the 2VO behind 8 weeks, the 2VO behind 12 weeks, the 2VO 16 weeks.
4. measure dizzy incubation period: regulate rotation inducing instrument rotary speed 200r/min.The rat rotation was placed in charged insulating 50 * 50 * 40 experimental boxs on every side in bottom in 1 minute, at once electric shock.(cylindrical rubber of the high 10cm of a diameter 6.5cm is put by experimental box central authorities).Rat stops to jumping onto rubber column escape electric shock and keeping being dizzy incubation period in 30 seconds at rubber column from rotation.Incubation period, long prompt was dizzy serious more more.Each measured once dizzy incubation period to all animals 16 weeks behind 12 weeks, the 2VO behind 8 weeks, the 2VO before 2VO, behind the 2VO.
Two, experimental result
1. oral liquid of the present invention is to the influence of chronic insufficient cerebral blood supply learning and memory function: Y shape maze test learning and memory in rats achievement has 9 correct required number of shocks to represent to reach before all rat modelings in continuous 10 times, how much represents the quality of learning and memory function with reaching 9/10 correct required number of shocks.As shown in table 1, correct learning and memory function approximately needs about 18-20 time before the rat 2VO.Behind the rat 2VO, along with time lengthening, the learning and memory achievement descends gradually.The correct learning and memory achievement of 2V012 week rat is electric shock about 39.5 times, and 16 weeks were about 58.3 times; Nimodipine group and 2VO group no significant difference, P＞0.05.12 weeks of oral liquid group, the correct learning and memory achievement with 16 weeks was that shock count is respectively 29.2 and 43.2 times, and organizing with 2VO relatively has notable difference, P＜0.05.Point out oral liquid of the present invention can effectively improve the 2VO learning and memory function.
Table 1 oral liquid of the present invention is to the influence of chronic insufficient cerebral blood supply learning and memory function
* compare P＜0.05 with the 2VO group
2. the influence that oral liquid of the present invention is dizzy to the chronic insufficient cerebral blood supply rat: as shown in table 2, be about 96 seconds dizzy incubation period before all rat modelings.Behind the rat 2VO, along with time lengthening increases dizzy incubation period.As shown in table 1, be respectively 17.3 ± 2.3,39.5 ± 4.3,58.3 ± 8.5 the dizzy incubation period that 2VO organizes 8 weeks, 12 weeks, 16 weeks, and notable difference arranged, P＞0.05 before the 2VO.Nimodipine treatment each time point of back and 2VO group no significant difference, P＞0.05.Be respectively correct 112.12 ± 16,127.41 ± 26,134.14 ± 31 the dizzy incubation periods in oral liquid group 12 week and 16 weeks, notable difference, P＜0.05 relatively arranged with the 2VO group.Point out oral liquid of the present invention can effectively improve dizzy effect incubation period of 2VO rat.
Table 2 oral liquid is to the dizzy preclinical influence of chronic insufficient cerebral blood supply rat
# and sham operated rats be P＜0.05 relatively; * compare P＜0.05 with the 2VO group
Three, discuss
1992, Torre etc. reported that at first ligation rat bilateral carotid causes the chronic insufficient cerebral blood supply model to succeed.Subsequently studies confirm that 2VO rat hippocampus CA1 district neural degeneration, cortex atrophy, white matter are loose, microglia hypertrophy and capillary bed change etc.The 2VO rat promptly enters chronic phase after 3 weeks, and frontal lobe appears to the 2VO3 rat in rat after 3 months, Hippocampus M type cholinoceptor combination rate descends, and monoamine class mediator changes and the energy metabolism compensatory activates and neuroethology changes.
This experimentation confirms that aspect learning and memory mensuration the correct learning and memory achievement in 12 weeks of oral liquid group of the present invention and 16 weeks is that shock count is respectively 29.2 and 43.2 times, with the 2VO group notable difference, P＜0.05 is arranged relatively.Point out pharmaceutical composition of the present invention can effectively improve the 2VO learning and memory function; In dizzy incubation period of influence experiment, be respectively correct 112.12 ± 16,127.41 ± 26,134.14 ± 31 the dizzy incubation periods in 12 weeks of oral liquid group of the present invention and 16 weeks, with the 2VO group notable difference, P＜0.05 are arranged relatively.Point out pharmaceutical composition of the present invention can effectively improve dizzy effect incubation period of 2VO rat.
In sum, this experimental result shows that this pharmaceutical composition has the chronic insufficient cerebral blood supply of improvement rat blood circulation, improves effects such as the dizziness that causes because of chronic cerebral ischemia and dysmnesia.
The specific embodiment
The present invention is further illustrated below in conjunction with embodiment, and following this embodiment only is used to the present invention is described and to the present invention without limits.
Embodiment 1
Prescription: Cornu Cervi Pantotrichum 20g, Radix Polygoni Multiflori Preparata 600g, Herba Epimedii 450g, Rhizoma Zingiberis 100g, Radix Glycyrrhizae 60g, Fructus Jujubae 100g, vitamin B
11g;
Preparation: the material of getting it filled according to the above ratio; Rhizoma Zingiberis is extracted volatile oil, and medicinal residues and Radix Polygoni Multiflori Preparata, Herba Epimedii, Fructus Jujubae, Radix Glycyrrhizae decoct with water three times, and 2 hours for the first time, second and third time each 1 hour, merge extractive liquid, filters, and filtrate is condensed into fluid extract, adds ethanol precipitation, filters filtrate for later use; With Cornu Cervi Pantotrichum extracting in water 5 times, the time was followed successively by 4,4,3,3,2 hours, filtered merging filtrate respectively, be concentrated into 1/2 of primary dose, add Cera Flava, leave standstill solidify fully to the Cera Flava layer after, remove the dewax layer, sucking filtration adds 80% ethanol to clear and bright, room temperature left standstill 24 hours, filtered filtrate recycling ethanol, be concentrated in right amount, add ethanol, placed 24 hours under the room temperature, filter, filtrate recycling ethanol adds water and ethanol and regulates concentration to 10% (contain very is 20%～30%); With above-mentioned medicinal liquid, Cornu Cervi Pantotrichum extracting solution and simple syrup mixing add Rhizoma Zingiberis volatile oil, and vitamin B1 and benzoic acid mix, and leave standstill, and add water, promptly.
Embodiment 2
Prescription: Cornu Cervi Pantotrichum 30g, Radix Polygoni Multiflori Preparata 625g, Herba Epimedii 500g, Rhizoma Zingiberis 125g, Radix Glycyrrhizae 62.5g, Fructus Jujubae 125g, vitamin B
15g;
Preparation: said medicine is pulverized, crossed 100 mesh sieves, add refined honey, make honeyed pill.
Embodiment 3
Prescription: Cornu Cervi Pantotrichum 40g, Radix Polygoni Multiflori Preparata 650g, Herba Epimedii 550g, Rhizoma Zingiberis 150g, Radix Glycyrrhizae 65g, Fructus Jujubae 150g, vitamin B
110g;
Preparation: said medicine is pulverized, crossed 100 mesh sieves, stir, add excipient starch, pelletize, granulate is gone into the tablet machine tabletting then, makes tablet.
Claims (5)
1. the application of pharmaceutical composition in preparation treatment chronic insufficient cerebral blood supply medicine, wherein the weight proportion of each flavour of a drug is as follows:
20～40 parts in Cornu Cervi Pantotrichum, 600～650 parts of Radix Polygoni Multiflori Preparatas, 450～550 parts of Herba Epimedii, 100～150 parts of Rhizoma Zingiberiss, 60～65 parts in Radix Glycyrrhizae, 100～150 parts in Fructus Jujubae, vitamin B
11～10 part.
2. application according to claim 1, wherein the weight proportion of each flavour of a drug is as follows:
30 parts in Cornu Cervi Pantotrichum, 625 parts of Radix Polygoni Multiflori Preparatas, 500 parts of Herba Epimedii, 125 parts of Rhizoma Zingiberiss, 62.5 parts in Radix Glycyrrhizae, 125 parts in Fructus Jujubae, vitamin B
15 parts.
3. the application of pharmaceutical composition in the hypomnesis medicine that preparation treatment chronic insufficient cerebral blood supply causes, wherein the weight proportion of each flavour of a drug is as follows:
20～40 parts in Cornu Cervi Pantotrichum, 600～650 parts of Radix Polygoni Multiflori Preparatas, 450～550 parts of Herba Epimedii, 100～150 parts of Rhizoma Zingiberiss, 60～65 parts in Radix Glycyrrhizae, 100～150 parts in Fructus Jujubae, vitamin B
11～10 part.
4. the application of pharmaceutical composition in the vertigo medicament that preparation treatment chronic insufficient cerebral blood supply causes, wherein the weight proportion of each flavour of a drug is as follows:
20～40 parts in Cornu Cervi Pantotrichum, 600～650 parts of Radix Polygoni Multiflori Preparatas, 450～550 parts of Herba Epimedii, 100～150 parts of Rhizoma Zingiberiss, 60～65 parts in Radix Glycyrrhizae, 100～150 parts in Fructus Jujubae, vitamin B
11～10 part.
5. the application of pharmaceutical composition in the encephalopathy medicine that preparation treatment chronic insufficient cerebral blood supply causes, wherein the weight proportion of each flavour of a drug is as follows:
20～40 parts in Cornu Cervi Pantotrichum, 600～650 parts of Radix Polygoni Multiflori Preparatas, 450～550 parts of Herba Epimedii, 100～150 parts of Rhizoma Zingiberiss, 60～65 parts in Radix Glycyrrhizae, 100～150 parts in Fructus Jujubae, vitamin B
11～10 part.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB200410019831XA CN100450539C (en) | 2004-06-30 | 2004-06-30 | Use of medicinal composition containing pilose antler for treating chronic brain blood supply deficiency |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB200410019831XA CN100450539C (en) | 2004-06-30 | 2004-06-30 | Use of medicinal composition containing pilose antler for treating chronic brain blood supply deficiency |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1714857A CN1714857A (en) | 2006-01-04 |
| CN100450539C true CN100450539C (en) | 2009-01-14 |
Family
ID=35821219
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB200410019831XA Expired - Fee Related CN100450539C (en) | 2004-06-30 | 2004-06-30 | Use of medicinal composition containing pilose antler for treating chronic brain blood supply deficiency |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100450539C (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118203643A (en) * | 2024-03-20 | 2024-06-18 | 吉林敖东延边药业股份有限公司 | Application of Anshenbunao solution in the preparation of drugs for the prevention and treatment of Alzheimer's disease |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1215609A (en) * | 1998-10-24 | 1999-05-05 | 张兴国 | Medicinal liquor for treating cerebral embolism |
-
2004
- 2004-06-30 CN CNB200410019831XA patent/CN100450539C/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1215609A (en) * | 1998-10-24 | 1999-05-05 | 张兴国 | Medicinal liquor for treating cerebral embolism |
Non-Patent Citations (4)
| Title |
|---|
| 中华人民共和国卫生部药品标准中药成方制剂第二册. 中华人民共和国卫生部药典委员会，78. 1990 |
| 中华人民共和国卫生部药品标准中药成方制剂第二册. 中华人民共和国卫生部药典委员会，78. 1990 * |
| 中西医结合治疗低血压性脑供血不足33例. 梁柯.右江医学，第27卷第1期. 1999 |
| 中西医结合治疗低血压性脑供血不足33例. 梁柯.右江医学，第27卷第1期. 1999 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1714857A (en) | 2006-01-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1872329A (en) | Application of medication composition of containing giant gen-seng in preparing medicine for treating insufficiency of blood supply for brain | |
| CN100592918C (en) | Application of medication composition containing magnolia vine fruit in preparing medicine for treating insufficiency of blood supply for brain | |
| CN100450539C (en) | Use of medicinal composition containing pilose antler for treating chronic brain blood supply deficiency | |
| CN100411652C (en) | Use of medicinal composition in preparing medicine for treating chronic brain blood supply deficiency | |
| CN1872214B (en) | Application of medication composition of containing notoperygium root in preparing medication for treating chronic insufficiency of supplying blood for brain | |
| US20170136083A1 (en) | Pharmaceutical composition for preventing and treating senile dementia and preparation method thereof | |
| CN100455316C (en) | Use of medicinal composition containing ligusticum wallichii for treating chronic brain blood supply deficiency | |
| CN1872187B (en) | Application of medication composition of containing astragalus root in preparing medication for treating chronic insufficiency of supplying blood for brain | |
| CN1872276B (en) | Application of medication composition of containing extractive of astragalus root in preparing medicine for treating insufficiency of blood supply for brain | |
| CN1872287A (en) | Application of medication composition of containing gastrodia tuber in preparing medicine for treating insufficiency of blood supply for brain | |
| CN1872213B (en) | Application of medication composition of containing peach kernel in preparing medication for treating chronic insufficiency of supplying blood for brain | |
| CN1872319B (en) | Application of medication composition of containing polygala root in preparing medicine for treating insufficiency of blood supply for brain | |
| CN1872297B (en) | Application of medication composition of Guangdong date in preparing medicine for treating chronic insufficiency of blood supply for brain | |
| CN100563699C (en) | A kind of application of pharmaceutical composition in the medicine of preparation treatment chronic insufficient cerebral blood supply that contains Rhizoma Ligustici | |
| CN100548362C (en) | A kind of Rhizoma Typhonii pharmaceutical composition that contains is preparing the application for the treatment of in the chronic insufficient cerebral blood supply medicine | |
| CN1872081B (en) | Application of kudzuvine root flavone in preparing medicine for treating chronic insufficiency of blood supply for brain | |
| CN1872170B (en) | Application of medication composition of containing corydalis tuber in preparing medication for treating chronic insufficiency of supplying blood for brain | |
| CN1872178B (en) | Application of medication composition of containing white peony root in preparing medication for treating chronic insufficiency of supplying blood for brain | |
| CN1872154B (en) | Application of medication composition of containing Yunnan red sage root in preparing medication for treating chronic insufficiency of supplying blood for brain | |
| CN1872286B (en) | Application of medication composition of containing notoginseng in preparing medicine for treating insufficiency of blood supply for brain | |
| CN100563692C (en) | A kind of application of pharmaceutical composition in the medicine of preparation treatment chronic insufficient cerebral blood supply that contains Magnetitum | |
| CN100563702C (en) | A kind of application of pharmaceutical composition in the medicine of preparation treatment chronic insufficient cerebral blood supply that contains Fructus Gardeniae | |
| CN100592911C (en) | Application of medication composition containing BV6 in preparing medication for treating chronic insufficiency of supplying blood for brain | |
| CN1872291A (en) | Application of medication composition of containing uncaria in preparing medicine for treating insufficiency of blood supply for brain | |
| CN1714851A (en) | Use of medicinal composition containing gastrodia elata for treating chronic brain blood supply deficiency |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee |
Owner name: TASLY PHARMACEUTICAL GROUP CO., LTD. Free format text: FORMER NAME: TIANJIN TASLY PHARMACEUTICAL CO., LTD. |
|
| CP01 | Change in the name or title of a patent holder |
Address after: 300402, No. 1, Liaohe East Road, Beichen Science Park, Beichen District, Tianjin Patentee after: Tasly Pharmaceutical Group Co., Ltd. Address before: 300402, No. 1, Liaohe East Road, Beichen Science Park, Beichen District, Tianjin Patentee before: Tianjin Tianshili Pharmaceutical Co., Ltd. |
|
| CP03 | Change of name, title or address |
Address after: 300410 Tianjin city Beichen District Huaihe road and road intersection Dingjiang tianzhijiao Park forensic Center for Intellectual Property Department Patentee after: Tasly Pharmaceutical Group Limited by Share Ltd Address before: 300402, No. 1, Liaohe East Road, Beichen Science Park, Beichen District, Tianjin Patentee before: Tasly Pharmaceutical Group Co., Ltd. |
|
| CP03 | Change of name, title or address | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090114 Termination date: 20190630 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |